These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 18617423)

  • 1. Mapping of the norepinephrine transporter in the human brain using PET with (S,S)-[18F]FMeNER-D2.
    Takano A; Varrone A; Gulyás B; Karlsson P; Tauscher J; Halldin C
    Neuroimage; 2008 Aug; 42(2):474-82. PubMed ID: 18617423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative analysis of norepinephrine transporter in the human brain using PET with (S,S)-18F-FMeNER-D2.
    Arakawa R; Okumura M; Ito H; Seki C; Takahashi H; Takano H; Nakao R; Suzuki K; Okubo Y; Halldin C; Suhara T
    J Nucl Med; 2008 Aug; 49(8):1270-6. PubMed ID: 18632811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET Quantification of the Norepinephrine Transporter in Human Brain with (
    Moriguchi S; Kimura Y; Ichise M; Arakawa R; Takano H; Seki C; Ikoma Y; Takahata K; Nagashima T; Yamada M; Mimura M; Suhara T
    J Nucl Med; 2017 Jul; 58(7):1140-1145. PubMed ID: 27980046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging the norepinephrine transporter with positron emission tomography: initial human studies with (S,S)-[18F]FMeNER-D2.
    Takano A; Gulyás B; Varrone A; Karlsson P; Schou M; Airaksinen AJ; Vandenhende F; Tauscher J; Halldin C
    Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):153-7. PubMed ID: 17909794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S,S)-[18F]FMeNER-D2.
    Sekine M; Arakawa R; Ito H; Okumura M; Sasaki T; Takahashi H; Takano H; Okubo Y; Halldin C; Suhara T
    Psychopharmacology (Berl); 2010 Jun; 210(3):331-6. PubMed ID: 20309528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2.
    Seneca N; Gulyás B; Varrone A; Schou M; Airaksinen A; Tauscher J; Vandenhende F; Kielbasa W; Farde L; Innis RB; Halldin C
    Psychopharmacology (Berl); 2006 Sep; 188(1):119-27. PubMed ID: 16896954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluations of norepinephrine transporter radioligands with reference tissue models in rhesus monkeys: (S,S)-[18F]FMeNER-D2 and (S,S)-[11C]MeNER.
    Takano A; Gulyás B; Varrone A; Halldin C
    Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1885-91. PubMed ID: 19565240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain.
    Schou M; Halldin C; Sóvágó J; Pike VW; Hall H; Gulyás B; Mozley PD; Dobson D; Shchukin E; Innis RB; Farde L
    Synapse; 2004 Aug; 53(2):57-67. PubMed ID: 15170818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The norepinephrine transporter (NET) radioligand (S,S)-[18F]FMeNER-D2 shows significant decreases in NET density in the human brain in Alzheimer's disease: a post-mortem autoradiographic study.
    Gulyás B; Brockschnieder D; Nag S; Pavlova E; Kása P; Beliczai Z; Légrádi A; Gulya K; Thiele A; Dyrks T; Halldin C
    Neurochem Int; 2010; 56(6-7):789-98. PubMed ID: 20211213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress.
    Logan J; Wang GJ; Telang F; Fowler JS; Alexoff D; Zabroski J; Jayne M; Hubbard B; King P; Carter P; Shea C; Xu Y; Muench L; Schlyer D; Learned-Coughlin S; Cosson V; Volkow ND; Ding YS
    Nucl Med Biol; 2007 Aug; 34(6):667-79. PubMed ID: 17707807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2.
    Moriguchi S; Takano H; Kimura Y; Nagashima T; Takahata K; Kubota M; Kitamura S; Ishii T; Ichise M; Zhang MR; Shimada H; Mimura M; Meyer JH; Higuchi M; Suhara T
    Int J Neuropsychopharmacol; 2017 Dec; 20(12):957-962. PubMed ID: 29016875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body biodistribution, radiation dosimetry estimates for the PET norepinephrine transporter probe (S,S)-[18F]FMeNER-D2 in non-human primates.
    Seneca N; Andree B; Sjoholm N; Schou M; Pauli S; Mozley PD; Stubbs JB; Liow JS; Sovago J; Gulyás B; Innis R; Halldin C
    Nucl Med Commun; 2005 Aug; 26(8):695-700. PubMed ID: 16000987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S,S)-[18F]FMeNER-D2: a human whole-body PET study.
    Takano A; Halldin C; Varrone A; Karlsson P; Sjöholm N; Stubbs JB; Schou M; Airaksinen AJ; Tauscher J; Gulyás B
    Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):630-6. PubMed ID: 18000665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)-[(11)C]O-methylreboxetine and HRRT.
    Ding YS; Singhal T; Planeta-Wilson B; Gallezot JD; Nabulsi N; Labaree D; Ropchan J; Henry S; Williams W; Carson RE; Neumeister A; Malison RT
    Synapse; 2010 Jan; 64(1):30-8. PubMed ID: 19728366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[(11)C]O-methylreboxetine.
    Li CS; Potenza MN; Lee DE; Planeta B; Gallezot JD; Labaree D; Henry S; Nabulsi N; Sinha R; Ding YS; Carson RE; Neumeister A
    Neuroimage; 2014 Feb; 86():306-10. PubMed ID: 24121204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of 11C-labelled (R)-OHDMI and CFMME and their evaluation as candidate radioligands for imaging central norepinephrine transporters with PET.
    Schou M; Pike VW; Sóvágó J; Gulyás B; Gallagher PT; Dobson DR; Walter MW; Rudyk H; Farde L; Halldin C
    Bioorg Med Chem; 2007 Jan; 15(2):616-25. PubMed ID: 17123820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of serotonin transporter availability with [11C]MADAM--a comparison between the ECAT HRRT and HR systems.
    Schain M; Tóth M; Cselényi Z; Stenkrona P; Halldin C; Farde L; Varrone A
    Neuroimage; 2012 Mar; 60(1):800-7. PubMed ID: 22227138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of norepinephrine transporter gene variants on NET binding in ADHD and healthy controls investigated by PET.
    Sigurdardottir HL; Kranz GS; Rami-Mark C; James GM; Vanicek T; Gryglewski G; Kautzky A; Hienert M; Traub-Weidinger T; Mitterhauser M; Wadsak W; Hacker M; Rujescu D; Kasper S; Lanzenberger R
    Hum Brain Mapp; 2016 Mar; 37(3):884-95. PubMed ID: 26678348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S,S)-[(18)F]FMeNER-D (2).
    Takano A; Gulyás B; Varrone A; Maguire RP; Halldin C
    Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1308-14. PubMed ID: 19300997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [18F]FMeNER-D2: reliable fully-automated synthesis for visualization of the norepinephrine transporter.
    Rami-Mark C; Zhang MR; Mitterhauser M; Lanzenberger R; Hacker M; Wadsak W
    Nucl Med Biol; 2013 Nov; 40(8):1049-54. PubMed ID: 24100201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.